FGL

Neural cell adhesion molecule (NCAM) has biological functions such as inducing neural neogenesis; promoting neural differentiation; and protecting neural cells, and plays a key regulatory role in the development and function of the nervous system.

FGL is a bioactive peptide containing 15 amino acids designed according to the spatial structure of NCAM and its binding site with fibroblast growth factor receptor. As the functional core fragment of NCAM, FGL not only protects the nerves and induces neural differentiation, but also possesses anti-inflammatory and regulating neural plasticity, etc. FGL has been used in the treatment of neuropsychiatric diseases, such as ischemic brain injury, cognitive disorders of the elderly, Alzheimer’s disease and depression. It is of great value in the treatment of neuropsychiatric diseases such as ischemic brain damage, cognitive disorders in the elderly, Alzheimer’s disease and depression.

In addition, the results of clinical trials show that FGL is safe for human beings, and the clinical phase I trial for Alzheimer’s disease is underway. FGL is likely to become an effective drug for the treatment of neuropsychiatric diseases, and has a broad clinical application prospect.